Relmada Therapeutics Inc. (4E2)
Munich
4.06
0.00 (0.00%)
Real-time Data
06:00 AM
Day's Range
4.064.06
52 wk Range
0.53506.45
Financial Statements - 4E2 - Relmada Therapeutics Inc.
Revenue
0
Net Income
-57.38M▲ 28.3%
EBITDA
-59.41M▲ 29.5%
Free Cash Flow
-45.78M▲ 11.5%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -59.10M | -83.89M | -103.70M | -161.24M | -125.70M | -60.83M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 319.04K | 381.66K | -241.15K | 1.54M | -1.24M | -16.94K |
| Pre Tax Income | -57.38M | -79.97M | -98.79M | -157.04M | -125.75M | -59.45M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -57.38M | -79.97M | -98.79M | -157.04M | -125.75M | -59.45M |
| EPS Basic | -1.45 | -2.65 | -3.28 | -5.3 | -7.16 | -3.81 |
| EPS Diluted | -1.45 | -2.65 | -3.28 | -5.3 | -7.16 | -3.81 |
| Basic Shares Outstanding | 39.47M | 30.16M | 32.58M | 30.83M | 18.26M | 16.22M |
| Diluted Shares Outstanding | 39.47M | 30.16M | 32.58M | 30.83M | 18.26M | 16.22M |
| Ebit | -59.10M | -83.89M | -103.70M | -161.24M | -125.70M | -60.83M |
| Ebitda | -59.41M | -84.27M | -103.46M | -156.44M | -124.45M | -60.81M |
| Net Income Continuous Operations | -57.38M | -79.97M | -98.79M | -157.04M | -125.75M | -59.45M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
